GlassScriptPhysician profile
Roger Craig Netzer
NPI 1205831864
$8,658.94
in general payments reported to CMS, 2019-2025
27 companies · $595 in 2025
The $595 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $1,103 · 2021: $1,450 · 2022: $1,681 · 2023: $995 · 2024: $1,150 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.84 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,349.98 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Lilly USA, LLC | $1,214.45 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,063.44 | 2019-2025 | Airsupra, Tezspire, Breztri |
| E.R. Squibb & Sons, L.L.C. | $853.67 | 2019-2024 | Eliquis |
| Pfizer INC. | $581.28 | 2019-2024 | |
| Novo Nordisk INC | $496.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $419.17 | 2019-2025 | Otezla, Repatha, Evenity |
| Kowa Pharmaceuticals America, INC. | $378.26 | 2020-2024 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $364.84 | 2021-2024 | |
| Amarin Pharma, INC. | $357.10 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $295.13 | 2019-2023 | Verquvo, Belsomra |
| Glaxosmithkline, LLC. | $225.86 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $209.32 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $196.71 | 2019-2021 | |
| United Therapeutics Corporation | $125.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $109.95 | 2024-2025 | Tremfya, Stelara |
| Axsome Therapeutics, INC. | $96.91 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $71.68 | 2021-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $45.79 | 2019 | |
| Exact Sciences Corporation | $45.24 | 2025 | The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $40.21 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.32 | 2022 | |
| Radius Health, INC. | $27.45 | 2020 | |
| Abbvie INC. | $19.44 | 2021 | |
| Boston Scientific Corporation | $16.87 | 2019 | |
| Astellas Pharma US INC | $13.18 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Netzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.